OnKure raises $150M in PIPE; plans IND filings for PI3Kα pan-mutant inhibitors in H1 2027

OnKure Therapeutics, Inc.

Private placement of ~26.7M shares at $4.15 and ~9.4M pre-funded warrants; gross proceeds ~$150M.
Proceeds to fund development of PI3Kα pan-mutant inhibitors OKI-345 (breast cancer) and OKI-355 (vascular anomalies).
IND submissions for OKI-345 and OKI-355 planned for H1 2027; no further independent development of OKI-219.
Dr. Liam Ratcliffe appointed to board effective at closing, designated by lead investor AI Biotechnology.
Officers/directors and company subject to 180-day lock-up (or until registration effective) on share issuance/sales.

item 1.01 item 3.02 item 5.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

OnKure Therapeutics, Inc. entered into Purchase Agreement with certain institutional accredited investors valued at approximately $150.0 million (effective 2026-03-27).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional accredited investors
Value: approximately $150.0 million
Effective: 2026-03-27

Exact text from the filing

On March 27, 2026, OnKure Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (i) 26,713,636 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $4.15 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants” and together with the Shares, the “Securities”) to purchase 9,430,959 shares of Common Stock (the “Warrant Shares”), at a purchase price of $4.1499 per underlying Warrant Share (the “Private Placement”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

OnKure Therapeutics, Inc. entered into Registration Rights Agreement with the Company and the Investors (effective 2026-03-27).

Action: entry
Agreement: equity purchase
Counterparty: the Company and the Investors
Effective: 2026-03-27

Exact text from the filing

the Company and the Investors also entered into a Registration Rights Agreement, dated March 27, 2026 (the “Registration Rights Agreement”), providing for the registration for resale of the Shares and the Warrant Shares, pursuant to a registration statement (the “Registration Statement”) to be filed with the SEC within 30 days after the Closing Date.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-130283

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.